Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
This production block consists of chemical synthesis reactions and clean rooms areas to produce final API
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Nous-209 has been developed using the Nouscom's viral vector platform
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Subscribe To Our Newsletter & Stay Updated
